Negative Mouth and Saliva Effects Linked to Glucagon-Like Peptide-1 Receptor Agonist Medications

The use of glucagon-like peptide-1 receptor agonists and tirzepatide for Type 2 diabetes and obesity raises concerns about oral and salivary side effects.

• Potential oral and salivary adverse effects may arise from the use of these medications.
• Mechanisms for these effects could involve changes in saliva production or oral mucosal health.
• The implications for oral medicine practice may include the need for monitoring patient oral health.
• Existing evidence on these effects is limited and requires further investigation.

Simplified